Jasper Therapeutics Inc’s recently made public that its Director WIGGANS THOMAS G acquired Company’s shares for reported $99630.0 on Sep 22 ’25. In the deal valued at $2.43 per share,41,000 shares were bought. As a result of this transaction, WIGGANS THOMAS G now holds 41,000 shares worth roughly $72980.0.
Then, Lucas Svetlana bought 20,000 shares, generating $48,600 in total proceeds. Upon buying the shares at $2.43, the Director now owns 20,000 shares.
Before that, MARTELL RON bought 41,000 shares. Jasper Therapeutics Inc shares valued at $99,630 were divested by the President and CEO at a price of $2.43 per share. As a result of the transaction, MARTELL RON now holds 74,118 shares, worth roughly $0.13 million.
RBC Capital Mkts downgraded its Jasper Therapeutics Inc [JSPR] rating to a Sector perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who decreased its forecast for the stock in early July from “an Outperform” to “a Market perform”. William Blair also remained covering JSPR and has decreased its forecast on July 07, 2025 with a “Mkt perform” recommendation from previously “an Outperform” rating. Cantor Fitzgerald revised its rating on July 07, 2025. It rated JSPR as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of JSPR
On Friday, Jasper Therapeutics Inc [NASDAQ:JSPR] saw its stock fall -2.73% to $1.78. Over the last five days, the stock has lost -21.93%. Jasper Therapeutics Inc shares have fallen nearly -92.05% since the year began. Nevertheless, the stocks have fallen -91.67% over the past one year. While a 52-week high of $26.05 was reached on 01/02/25, a 52-week low of $1.80 was recorded on 11/07/25.
Levels Of Support And Resistance For JSPR Stock
The 24-hour chart illustrates a support level at 1.6450, which if violated will result in even more drops to 1.5100. On the upside, there is a resistance level at 1.8700. A further resistance level may holdings at 1.9600.
How much short interest is there in Jasper Therapeutics Inc?
A steep rise in short interest was recorded in Jasper Therapeutics Inc stocks on 2025-10-15, growing by 0.39 million shares to a total of 1.55 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 1.16 million shares. There was a rise of 24.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 13, 2025 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $38 price target.
